BioRegenx, Inc.
BRGX
$0.01
$0.0041.11%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 507.80K | 446.00K | 515.10K | 460.50K | 596.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 507.80K | 446.00K | 515.10K | 460.50K | 596.00K |
| Cost of Revenue | 81.40K | 93.50K | 109.10K | 137.80K | 114.40K |
| Gross Profit | 426.40K | 352.50K | 406.00K | 322.70K | 481.60K |
| SG&A Expenses | 434.90K | 459.70K | 598.60K | 1.86M | 246.90K |
| Depreciation & Amortization | -- | -- | -- | 562.10K | 562.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 516.20K | 553.20K | 707.80K | 2.56M | 923.30K |
| Operating Income | -8.50K | -107.30K | -192.60K | -2.10M | -327.30K |
| Income Before Tax | -80.60K | -178.30K | -266.90K | -18.40M | -394.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -80.60K | -178.30K | -266.90K | -18.40M | -394.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.60K | -178.30K | -266.90K | -18.40M | -394.90K |
| EBIT | -8.50K | -107.30K | -192.60K | -2.10M | -327.30K |
| EBITDA | 3.90K | -69.90K | -180.20K | -1.53M | 247.20K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 960.87M | 959.21M | 956.99M | 971.71M | 956.53M |
| Average Diluted Shares Outstanding | 960.87M | 959.21M | 956.99M | 971.71M | 956.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |